To investigate the possibility of using hepatitis B virus transactivation activity of the HBVtat recombinant since a (HBV) as a vector, the tat gene from human immunodefiframeshift mutation in the pol gene did not affect the ciency virus type 1 (HIV-1) was inserted into the full-length recombinant tat function. The functional tat protein, there-HBV genome in-frame with the polymerase (pol) open fore, was most likely expressed as a Tat-Pol fusion proreading frame in the tether region and downstream of the duct. Endogenous polymerase assays showed that the pol preS1 promoter. We demonstrated that the tat gene was protein expressed from the HBVtat recombinant was still expressed with full activity in transactivating the HIV-1 long active although at a reduced level. Hepatitis B surface antiterminal repeat (LTR). The expression of the tat gene in gens and e antigen produced from this recombinant were the context of the HBV genome in chicken hepatoma and detected at similar levels as those produced from the wild human cervical carcinoma cells, however, was not as type. Notably, the capability of forming complete HBV parefficient as that in human hepatoblastoma cells, which ticles was still retained. These studies indicate the potential reflects the cellular and species specificity of promoters of of constructing HBV as a replicative vector. We also hepadnaviruses. Detection of RNA expressed from this showed that manipulation of a nonreplicative HBV vector HBVtat recombinant revealed transcription of the tat gene was possible. Expression of the HBV polymerase could be by two promoters: the core/pol promoter and the preS1 completely eliminated and replication of the nonreplicative promoter. A Pol-Tat fusion protein expressed by the HBV recombinant could be supported by Pol transcore/pol promoter did not seem to contribute to the tat complementation.
Introduction
compact and efficiently organized with overlapping open As we are faced with a number of diseases involving the reading frames (ORFs). 13, 14 Hepatitis B virus (HBV), the liver, particularly inherited single gene defects and viral prototype of hepadnaviruses and causative agent for diseases, a novel therapeutic approach using targeted human hepatitis, carries four major overlapping ORFs: gene transfer to this organ is of particular interest, preS1/preS2/S (collectively known as the envelope or especially strategies of using human viruses as vectors.
surface gene), preC/C, X and P. The envelope gene, In vitro protocols for transferring the low density lipoproencompassing the preS1, preS2 and S regions as delintein (LDL) receptor gene into hepatocytes using a retrovieated by three in-frame initiation codons, codes for three ral vector have been established. 1, 2 Adenoviral vectors envelope proteins: large (L), middle (M) and major (S). have also been used to deliver therapeutic genes, such as
The preC/C gene, including the preC and C regions as the genes for factors VIII 3 and IX 4, 5 and LDL receptor 6, 7 delineated by two in-frame initiation codons, codes for into liver cells. However, these viral vectors infect a wide secreted HBV e antigen (HBeAg) and capsid or core prorange of tissues, not specifically targeting to the liver. tein (HBcAg). The X gene codes for a transactivating proExpression of the transferred gene by adenoviral vectors, tein which has activity on HBV enhancers and other for example, is detected in different tissues after systemic cellular genes. 15 The P or polymerase (pol) gene has the administration 6, 8, 9 or via portal or splenic vein. 7, 10, 11 longest ORF. It encompasses about 80% of the entire viral Therefore, the use of hepadnaviruses which are hepatogenome and overlaps with the C-terminus of the preC/C tropic and possess strong liver-specific promoter and gene, the entire envelope gene and the N-terminus of the enhancer elements, 12 as vector systems, may provide a X gene. The C-terminus of the X gene also overlaps with more efficient means for gene delivery to the liver.
the N-terminus of the preC/C gene. The protein product Hepadnaviruses are among the smallest DNA viruses (Pol) encoded by the pol gene can be divided into three known, carrying only 3200 base pairs in their genome. major functional domains: the terminal protein domain at the N-terminus, the reverse transcriptase-DNA polymerase in the central domain and the RNase H domain at the C-terminus. 16, 17 The terminal protein and reverse preS1, preS2/S, X and core/pol promoters, 18 which regulate transcription of pregenomic and subgenomic messengers for expression of the corresponding genes, have been identified on the HBV genome. Almost all nucleotides are included in coding sequences and are therefore indispensable. Only the spacer or tether region may be nonessential for the pol gene function or HBV replication. 17, 19 To our knowledge, HBV or other hepadnaviruses have not yet been engineered and used as gene transfer tools. The unusually efficient genome of HBV is a factor that limits its genetic manipulation. Mutations, insertions or deletions in many regions of the HBV genome have deleterious effects on viral gene expression and replication. 17, [20] [21] [22] [23] [24] The tether region of the pol gene, however, seems to be dispensable for HBV replication and can be manipulated. Mutational and computer sequence analyses show that this region starts upstream of the preS1 gene and overlaps with the preS1 and preS2 regions. 17, 21 Part of the tether region, however, does not overlap with any other HBV genes. A mutational analysis of the pol gene of HBV has demonstrated that up to 90 codons of the intervening tether sequence can be deleted without significant loss of the endogenous polymerase activity. 17 It has also been shown that such a deletion has no effect on the RNA encapsidation process. 25 Mutants of HBV containing deletions in the preS1 region which overlaps the tether region are capable of replication. 23 The duck hepatitis B virus (DHBV) genome carrying the gene for protein A (123 amino acids) inserted in the tether region also retains the capability of expressing an active endogenous polymerase. 19 This region, moreover, toler- 
Results
EcoRI-EcoRI monomer of the HBVtat recombinant in a head to tail tandem configuration was subsequently constructed ( Figure 1b ). This dimeric construct was used for Construction of a replication-competent HBV vector To generate a replication-competent HBV vector, the studying the functions and characteristics of HBVtat. HBVtat recombinant was made by inserting the HIV-1 tat gene into the unique BstEII site in the tether region inFunctional expression of HIV-1 tat from HBVtat The expression of the tat gene from HBVtat was determframe with the pol ORF (Figure 1a) . The tat insert contained the entire tat ORF with its own initiation codon ined by transfection of human hepatoblastoma (HepG2), avian hepatoma (LMH) and human cervical carcinoma but without a stop codon. This insertion was 39 base pairs (bp) downstream of the preS1 promoter and did (HeLa) cells. HBVtat was cotransfected with a HIV-1 LTR-CAT reporter plasmid as described in Materials and med in HepG2 cells. The results indicate that the level of the transactivation of the X gene was as high as that of methods. The functional activity of the tat protein (Tat) was demonstrated by transactivation of the HIV-1 LTR wild-type HBV, whereas the transactivation activities of the core, pol or surface gene constructs were insignificant using CAT assay. In HepG2 cells, the basal activity of the CAT enzyme expressed from the HIV-1 LTR-CAT plas-( Figure 3 ). These results indicated that the high transactivation activity (86%) of HBVtat was due to the tat mid in the absence of Tat was low ( Figure 2 , lane 2), and only a residual transactivation activity was observed with insertion. the wild-type HBV construct (Figure 2, lane 3) . However, when HBVtat was present, the HIV-1 LTR was activated Expression of functional Tat independent of a Pol-Tat fusion to a level similar to that of the Tat-positive control ( Figure  2, lane 4 versus lane 1) . The result illustrated the Although the tat insert was designed to be expressed as a Pol-Tat fusion recombinant using the core-pol proexpression of the Tat function by HBVtat.
The tat gene function of HBVtat was also expressed in moter, the tat ORF was also in optimal proximity to the preS1 promoter ( Figure 1a (secreted human growth hormone) and to the amounts of hepatitis B e antigen (HBeAg) and hepatitis B surface antigens (HBsAg) secreted into the culture media. The reaction products were analyzed by agarose gel electrophoresis and autoradiography. Labeled DNA bands, corresponding to relaxed circular and linear doublestranded DNA genome and single-stranded DNA, were detected, albeit at reduced levels, as a result of the DNA polymerase activity of HBVtat ( Figure 6a and b, lane 1), indicating that the Pol-Tat fusion of HBVtat retained the polymerase function.
Compared with wild-type HBV, levels of endogenous polymerase activities in the intracellular core particles of HBVtat measured by a phosphoimager were about 4%, and in the extracellular viral particles of HBVtat were about 1.5%. Southern blot analysis of the intracellular core and extracellular viral particles of HBVtat confirmed these results (data not shown). Thus, the insertion of the ome would be efficiently and specifically introduced to target cells via infection. We thus determined whether The sizes of the pregenomic RNA (3.70 kb) and the subgenomic RNA (2.65 kb) expressed from HBVtat indiintact viral particles could be produced by HBVtat. Previous studies have established that the L protein is cated that the tat insert was included in transcripts from both the core-pol promoter and the preS1 promoter. It absolutely required for the formation and secretion of HBV-free virus particles. 29, 30 The insertion of the tat gene appeared that the tat gene sequence was also present in another RNA species of about 3.10 kb in length.
between the initiation codon and the promoter of preS1 gene might interrupt the expression of the L protein and, therefore, would affect production and secretion of viral Expression of functional polymerase activity by HBVtat To investigate the effect of the tat insertion on expression particles. The detection of endogenous polymerase activity in extracellular products of HBVtat-transfected and function of the pol gene, we performed an endogenous polymerase assay. This assay determines the coreHepG2 cells suggested that complete virus particles carrying the HBVtat recombinant genome had been syntheassociated viral DNA polymerase activity through incorporation of radioactively labeled deoxynucleotides into sized. To confirm this, we carried out an immunoaffinitycapture assay directly to analyze the secreted HBV the viral genome. Cytoplasmic lysates and culture media containing intracellular core and extracellular viral parparticles. Extracellular virus particles from transfected HepG2 ticles, respectively, were harvested from HepG2 cells transfected with wild-type HBV or HBVtat. The samples cells were captured using anti-HBV surface antibody as described in Materials and methods, and PCR was perwere normalized to an internal transfection control formed to detect the HBV genomic DNA. To eliminate however, a nonreplicative HBV vector may be favorable.
To this end, we constructed a HBV recombinant carrying contamination of plasmid DNA carried over from transfections, the samples were treated with DNase I before the Zeocin resistant gene (Zeocin R ) with a stop codon inframe with the pol gene (designated as HBVZeoS). The the immunoaffinity capturing. Cells transfected with a nonreplicative HBV construct (pTHBVP − ) were included Zeocin R insertion completely eliminated the expression of Pol and therefore rendered HBVZeoS replication incomas controls, treated or untreated with DNase I. No viral DNA could be detected in samples transfected with petent. Endogenous polymerase assay of the extracellular viral particles of HBVZeoS trans-complementated by Pol pTHBVP − if treated with DNase I, whereas plasmid DNA contaminants were detected if the samples were not was carried out to test whether synthesis of viral particles from a nonreplicative HBV vector construct was possible. treated with DNase I (Figure 7, lanes 3 and 4) . Thus, contamination of transfecting plasmids was eliminated by
The result showed that the DNA genome was synthesized from HBVZeoS after Pol complementation (Figure the DNase I treatment. HBV genomic DNA was detected in DNase I-treated culture media from cells transfected 9, lane 2 versus lane 1) and the trans-complemented polymerase activity was approximately 1.5-3.0% of that of the with wild-type HBV or HBVtat (Figure 7, lanes 1 and 2) but not from those transfected with the nonreplicative wild-type HBV. HBV plasmid or a mock plasmid (Figure 7, lanes 3 and 5) .
The synthesis of the HBVtat viral particles was also Discussion demonstrated by immunoprecipitation and Southern blot analysis (Figure 8 ). HBeAg and HBsAg produced by Gene therapy has become one of the most attractive therapeutic strategies and, if applicable, can treat both HBVtat were also examined, both of which were produced at levels similar to those of wild-type HBV (Table  acquired and genetic disorders. To be successful, however, gene therapy requires efficient tools for delivery 1). We concluded from these studies that complete viral particles were synthesized by HBVtat. and targeting, and the genes need to be expressed at therapeutic levels. For these reasons, viruses have been used as the best gene delivery mediators. Construction of a nonreplicative HBV vector: replication supported by Pol trans-complementation A number of inherited or metabolic disorders affect the liver. Patients with liver dysfunction often endure a short The above studies have shown the potential of constructing a replicative HBV vector. For therapeutic use, life span. Although liver transplantation has been suc- HBsAg and HBeAg produced were determined as S/N values as described by the manufacturer. у2.00 S/N is the cut-off rate for positive results. According to the manufacturer, у7.00 S/N of HBsAg detected is equivalent to 4-15 ng/ml concentration but the absolute concentration of HBeAg is not determined.
Figure 7 Immunoaffinity-capture assay to detect complete viral particles produced from HBVtat. The extracellular products were captured from culture media of cells transfected with wild-type HBV (lane 1), HBVtat (lane 2), nonreplicative HBV (lanes 3 and 4) and mock (lane 5) as described in Materials and methods. DNA of the captured HBV or HBVtat particles was determined by PCR and analyzed by 2% agarose gel electrophoresis. The actual amplified product was 114 bp in size. The DNA band detected in the sample of nonreplicative HBV without DNase I treatment (lane 4) was a contamination of the transfecting plasmid. Lane 6 marker, 1 kb DNA ladder (GIBCO BRL, Life Technologies); +, with
DNase I treatment; −, without DNase I treatment. Figure 6 . The DNA products were analyzed by agarose gel electrophoresis and autoradiography.
Figure 9 Endogenous polymerase activities in extracellular viral particles of nonreplicative HBVZeoS. HepG2 cells were cotransfected with wildtype HBV or HBVZeoS with pCHBVP (a Pol expression plasmid) or a mock plasmid. Endogenous polymerase assays were determined as described in the legend to
cessfully performed to save the lives of patients with and mortality risk. Gene therapy, therefore, is a promis-ing approach for correcting genetic liver defects. Owing licative and complete viral particles are formed. Analyses of the amounts of HBsAg and HBeAg produced from to its natural hepatotropism, hepadnaviruses could be the most effective tools for liver gene transfer and may overHBVtat suggest that the expression of these HBV structural genes is not significantly affected by the tat insercome the problems often associated with other liverdirected gene transfer systems. 31 tion. One major concern about the design of HBVtat was that the tat insertion might interfere with the L protein This article exploits the potential of using HBV as a gene delivery vector. In this study, we have demonsynthesis which has been shown to be absolutely necessary for virion assembly 29, 30 and binding to cellular strated that a foreign gene, HIV-1 tat, can be expressed and fully functional in the context of the full-length HBV receptor(s). 41, 42 The detection of extracellular viral particles indicates that the L protein is made and particles genome. Expression of the tat gene seems to be specific to human liver cells as it exhibits full transactivation are fully assembled. Therefore, it is highly possible that the recombinant viruses could infect liver cells. function in HepG2 cells. Diminished expression of the tat gene controlled by the endogenous HBV promoterAlthough attempts to produce defective and recombinant hepadnavirus particles have been reported, 43 this is enhancer elements in LMH and HeLa cells reflects the high species and cell-type specificity of hepadnathe first study to clearly demonstrate expression of a foreign gene in the context of a replication-competent viruses.
18,32-34 DHBV also replicates more efficiently in chicken hepatoma cells (LMH) than in human liver cells HBV genome. Recombinant viral particles are produced, even though the infectivity or transduction ability of the (HuH-7 and HepG2). 35 This shows the necessity of using HBV as a vector in hepatic gene transfer although it may recombinant viruses remains to be demonstrated. The majority of viral vectors developed for gene delivery are be advantageous to use nonhuman pathogenic hepadnaviruses as gene transfer tools.
replication defective; as a result, high titers of the recombinant viral vectors are usually required for efficient gene Northern blot analysis suggests that the tat gene inserted in the tether region is transcribed by both coretransduction. Since this HBV recombinant is replication competent, a low titer of the recombinant viral vector pol promoter and preS1 promoter. Since the Pol-Tat fusion expressed by the core-pol promoter is not may be sufficient for effective gene transfer. Alternatively, a nonreplicative HBV vector can be conaccountable for the transactivation activity of HBVtat, the functional Tat is most likely expressed as a Tat-Pol fusion structed. As demonstrated in this study by complete elimination of the pol gene expression, trans-compproduct using the tat initiation codon. It is known that Tat functions in the nucleus and HBV Pol interacts with lementation of Pol supported the synthesis of a nonreplicative HBV recombinant. This strategy has offered a the 5′epsilon sequence of the pregenomic RNA and is encapsidated into core particles in the cytoplasm. 36, 37 It is potential means of inserting a large foreign gene into the HBV genome. conceivable that the Pol-Tat fusion is encapsidated into the viral core particles in the cytoplasm and thus is not An HBV vector would naturally be the most appropriate tool for liver gene transfer. Due to its ability to infect transported into the nucleus where the tat protein would function. Since the entire Pol protein is required for nondividing hepatocytes, transduction rates of HBV vectors can be extremely efficient, particularly in comparison encapsidation and packaging of the cytoplasmic viral core particles, 25,26 the Tat-Pol fusion recombinant lacking to Moloney murine leukemia virus-derived retroviral vectors which require cell division for gene transfer. The the N-terminal domain of Pol would not be incorporated into the core particles. Therefore, the Tat-Pol fusion may fact that a large number of HBV-infected humans appear continuously to harbor the HBV genome and express migrate to the nucleus and confer transactivation activity. Multiple attempts for detecting the Tat-Pol fusion by HBsAg without pathogenic consequences offers a great advantage in terms of long-term maintenance and Western blot analysis and immunoprecipitation have not been successful, possibly due to the low levels of protein expression of a recombinant HBV vector bearing a desired gene. A recombinant HBV genome might be expression or the lack of optimal anti-Tat antisera.
Although the Tat-Pol fusion was most likely syntheattenuated to the extent that the HBV-associated pathogenesis is diminished. Further development and studies sized from transcripts of the preS1 promoter, we cannot officially exclude the possibility of its synthesis from the of HBV as therapeutic gene transfer vectors are necessary. Nevertheless, this preliminary study has demonpregenomic RNA by internal initiation, a mechanism used for the synthesis of HBV Pol. 38 strated the feasibility of constructing both replicative and nonreplicative HBV vectors. An additional 3.1 kb RNA containing the tat sequence was detected in HBVtat but not in wild-type HBV transfected cells. The near-genomic size suggests that this tat
Materials and methods
RNA species might originate from the pregenomic RNA. RNA splicing has been reported in hepadnaviruses. 39, 40 Sequence analysis of HBVtat has revealed consensus Plasmid construction and mutagenesis A basic plasmid, pTHBV, was constructed by subcloning splice donor sites on the HBV genome flanking the tat insert and a consensus splice acceptor site and a branch the full-length genome (EcoRI-EcoRI) of HBV adw2 subtype in the pT7T318U vector (Pharmacia Biotech, point within the tat sequence. Thus, we speculate that this 3.1 kb transcript is a spliced product of the pregenUppsala, Sweden). A 267-bp HIV-1 tat cDNA fragment with additional BstEII sites at both ends was amplified omic RNA of HBVtat.
Insertion of the tat gene in-frame with the pol gene has from plasmid pCEP-tat 44 by PCR using the upstream primer 5′ TGCGGGTCACCAATGGAGCCAGTAGAreduced the endogenous polymerase activity of the pol protein. It is possible that the insertion interferes with the TCCTAAT 3′ and the downstream primer 5′ ATATGGTGACCCTTCCGTGGGCCCTGTCGGGTC 3′ structural conformation of the Pol protein. Nevertheless, our study shows that the HBVtat recombinant is rep-(the BstEII sites are underlined). The Pfu polymerase (Stratagene, La Jolla, CA, USA) was used to minimize the surface antigen ORFs for the simultaneous expression of L, M and S surface proteins. 47 pCEP-tat carried the tat error rate of the polymerase. The PCR amplified tat fragment was subcloned into the unique BstEII site in the pol gene under the CMV promoter. 44 pLTR-CAT is a CAT reporter plasmid carrying the CAT gene under the HIV-ORF of the HBV genome. This construct is designated HBVtat. DNA sequencing confirmed the actual sequence.
1 LTR. 44 A nonreplicative HBVZeoS recombinant was conReplication-competent plasmids of wild-type HBV (pTHBV-d) and HBVtat (pTHBVT-d) were constructed structed by PCR subcloning the entire ORF of Zeocin R with a stop codon from pcDNA3.1/Zeo (Invitrogen) into by ligation head to tail of two copies of the full-length HBV (EcoRI-EcoRI) sequence and HBVtat (EcoRI-EcoRI) the unique BstEII site in the pol ORF of pTHBV. The PCR subcloning was performed using the upstream primer 5′ sequence, respectively, in the pT7T318U vector. The expression of these replication-competent HBV plasmids TGCGGGTCACCAATGGCCAAGTTGACCAGTGCC 3′ and the downstream primer 5′ ATATGGTGACCin a eukaryotic system is controlled by the HBV endogenous promoters. CTCAGTCCTGCTCCTCGGCCACGAAGTG 3′ (the BstEII sites are underlined). DNA sequencing confirmed Mutations of the X gene of HBVtat were performed by site-directed PCR mutagenesis. Three oligo primers were the actual sequence. Since the insertion had a stop codon and was in-frame with the pol gene, the pol expression designed. The upstream primer 5′ TTACTAGT-GCCATTTGTTCAGTGGTTCG 3′ was homologous to the was eliminated. A dimeric form of HBVZeoS (pTHBVZeoS-d) was constructed by ligation head to tail sequence at the unique SpeI site (underlined) located 142 bp upstream of the X gene. The downstream primer 5′ of two copies of the full-length HBVZeoS monomer in the pT7T318U vector and used for studying the replication of GTGCACACGGACCGGCAGATG 3′ anneals to the sequence at the unique RsrII site (underlined) located 197
HBVZeoS. bp downstream of the X gene. The mutated oligonucleotide 5′ ATACATCGTTTCCcTGGCTGCTAGGCTGTACTissue culture and transfection HepG2 and HeLa cells were cultured and maintained at TGCtAACTGGATCCTTC 3′ was targeted to the sequence at the unique NcoI site (underlined) at the initiation 37°C in 5% CO 2 in Auto-Pow MEM Eagle (modified) medium (ICN Biomedicals, Costa Mesa, CA, USA) supcodon of the X gene with change from A to C at the 1376 nucleotide (nt) and from C to T at the 1397 nt. These plemented with 10 mm sodium bicarbonate, 2 mm l-glutamate, 10% fetal bovine serum, 50 U/ml penicillin G changes abolished the initiation codon of the X gene and the original NcoI site with the addition of a stop codon sodium, 0.01 mg/ml streptomycin and 50 U/ml nystatin. LMH cells were cultured and maintained at 37°C in 5% (mutated nucleotides shown in boldface lower case). These mutations conserved the pol coding sequences.
CO 2 in a mixture of 1:1 Auto-Pow MEM Eagle (modified) and F12 (ICN Biomedicals) media with the same suppleThe mutations were performed by multiple PCR as described. 45 The mutated PCR fragment was then cut mentation as the HepG2 medium. Transfections were performed using Lipofectin with SpeI and RsrII and cloned into the unique sites in the HBVtat plasmid. A frameshift mutation of the pol ORF of (GIBCO BRL Life Technologies) for HepG2 cells and Lipofectamine (GIBCO BRL Life Technologies) for LMH HBVtat was generated by opening at the unique BspEI site (2331 nt) downstream of the initiation codon of the and HeLa cells using the procedure recommended by the manufacturer. In brief, cells were subcultured 20 h before pol gene and subsequently filling in (2332 to 2336 nt) with Klenow Fragment (GIBCO BRL Life Technologies, Gaitransfection. Cells were fed with fresh media 1 h before transfection. The plasmid DNA and Lipofectin or Lipothersburg, MD, USA). The mutation disrupted the reading frame of the pol gene. It, therefore, ablated the fectamine were each diluted into 300 l of unsupplemented medium. These two solutions were combined, expression of the tat insert as a Pol-Tat fusion recombinant. These mutated sites were verified by restriction incubated for 15-30 min at room temperature, and then applied to cells which had been washed twice with the mapping and DNA sequencing.
To construct a HBV core expression plasmid, pCHBVC, unsupplemented medium. The transfected cells were incubated at 37°C in 5% CO 2 . At 4 h after transfection, a 1500 nt fragment from the NlaIII site to the unique AvrII site, which includes the entire sequence of the core gene, an equal volume of the medium plus 10% fetal bovine serum (no supplementation of antibacterial agents) was was PCR amplified from the HBV genome containing plasmid, pKSVHBV1 46 and cloned into the pTZ19R vecadded with further incubation. About 20 h after transfection, cells were fed with the normal media. For the CAT tor (Pharmacia Biotech). The sequence between the HindIII and XbaI sites containing the core gene was subassay, a total amount of 5-10 g of DNA per 60-mm tissue culture dish was used. Cells were cotransfected cloned into the eukaryotic expression vector pcDNA I Amp (Invitrogen, San Diego, CA, USA). An HBV pol with the CAT reporter plasmid (pLTR-CAT) and the HBV plasmids or pCEP-tat (as a positive control) or a mock plasmid (pCHBVP) was constructed by subcloning a 2734 nt fragment containing the entire pol ORF from plasmid (as a negative control). The expression of HBV genes was assayed in HepG2 cells and a total amount of pKSVHBV1 into the pTZ19R vector by multiple cloning steps using restriction enzymes and PCR. The sequence 10 g of DNA per 60-mm tissue culture dish was used for transfection. Endogenous polymerase assays with Pol coding for the entire HBV pol ORF was cut and subcloned into the HindIII-EcoRV sites of the eukaryotic complementation were performed by cotransfection of equimolar quantities of the HBV plasmids and pCHBVP expression vector pcDNA I Amp. The subcloned sequences of these recombinant plasmids were verified into HepG2 cells. To assess transfection efficiency, all transfections were performed in the presence of human by restriction mapping and DNA sequencing. pSG-X was constructed by inserting the X gene into the EcoRI-BglII growth hormone plasmid pXGH5 (Nichols Institute Diagnostics, San Juan, Capistrano, CA, USA). Secreted sites of the eukaryotic expression vector pSG5 (Stratagene). A pSV45 plasmid carried the entire HBV human growth hormone was quantified by radioimmun-oassay. For preliminary detection and normalization of ture were added 11 m of each of dATP, dGTP and dTTP and 10 Ci of ␣ 32 P dCTP (3000 Ci/mmol; Dupont, Bosthe expression of HBV genes, HBeAg and HBsAg secreted in the cell media were determined by a ton, MA, USA). The reaction was performed at 37°C for 1 h. Chase buffer containing 0.2 mm unlabeled dCTP, and Microparticle Enzyme Immunoassay (MEIA) (Abbott Laboratories, Abbott Park, IL, USA).
0.1 mm of each of dATP, dGTP and dTTP was then added with a further incubation for 30 min. The reaction was stopped by adding an equal volume of 2 × proteinase K CAT assay CAT assays were performed as previously described. 44 buffer (300 mm NaCl, 40 mm EDTA, 20 mm Tris (pH 7.5), 2.5% sodium dodecyl sulfate (SDS)) and proteinase K to Cell lysates were prepared 48-72 h after transfection. An optimal amount of enzyme was used to ensure that the a final concentration of 1 g/l and incubated at 42°C for at least 2 h. The 32 P-labeled viral DNA was isolated CAT enzyme reaction rate was within the linear range. The converted products were separated by thin-layer by phenol-chloroform extraction and ethanol precipitation and by agarose gel electrophoresis. The 32 P-labeled chromatography and analyzed using a phosphoimager (BAS1000; Fuji, Kanagawa, Japan). The relative level of viral DNA was then transferred to a nylon membrane 48 and analyzed by autoradiography. The relative level of CAT enzyme was determined after normalization for transfection efficiency and total quantity of protein in the endogenous polymerase activity was analyzed by a phosphoimager. each cell lysate.
Isolation of extracellular HBV particles
Extraction of viral DNA and Southern blot analysis Viral materials pelleted from culture media or cell lysates Four to five days after transfection, the culture media from transfected cells were collected and centrifuged in were suspended in 50 mm Tris (pH 7.5), 150 mm NaCl and 10 mm EDTA. Nucleic acids were then purified by a Sorvall RT6000B Refrigerated Centrifuge (Dupont, Mississanga, ON, Canada) at 2500 g for 10 min to remove proteinase K digestion and phenol-chloroform extraction, and collected by ethanol precipitation. Viral DNA cellular debris. The extracellular viral particles were pelleted over a 25% sucrose cushion in 50 mm Tris (pH 8.0), was assayed by agarose gel electrophoresis and Southern blot analysis using standard methods.
48
150 mm NaCl and 10 mm EDTA solution using an ultracentrifuge SW 41 rotor at 150 000 g for 7-20 h. The pellets were resuspended in 50 mm Tris (pH 7.5), 150 mm NaCl Isolation of total RNA and Northern blot analysis Total RNA was harvested from transfected HepG2 cells and 10 mm EDTA. To remove DNA not present in virus particles or contaminating plasmids, 6 mm MgCl 2 and 100 using TRIzol reagent (GIBCO BRL Life Technologies) as described by the manufacturer. The amount of total RNA g/ml of DNase I were added to the suspension with incubation at 37°C for 30 min. The virus particles were was determined by spectrophotometer. An equal amount of RNA for each sample was separated on a 1.2% agaprecipitated by the addition of one-third volume of 26% PEG 8000, 1.4 m NaCl, and 25 mm EDTA. After centrifugrose-0.22M formaldehyde gel as described. 49 The RNA blot was prepared and hybridized to 32 P-labeled HIV-1 ation, the pellets were suspended in appropriate solutions. For endogenous polymerase assay, the pellets tat or HBV gene probes using standard methods. 48 were suspended in 30 l of polymerase buffer (50 mm Tris pH 8.0, 40 mm MgCl 2 , 50 mm NaCl, 1% Nonidet PIsolation of HBV particles by immunoaffinity capture 40 and 0.3% ␤-mercaptoethanol). The pellets were suspended in 50 mm Tris (pH 7.5), 150 mm NaCl and 10 mm Microtiter plate preparation: Each well of a high binding round-bottom plate (Corning 25802) (Corning, Cam-EDTA for DNA extraction and Southern blot analysis. For detection of complete HBV particles by immunobridge, MA, USA) was coated with a mouse anti-HBV surface antigen monoclonal antibody prepared and puraffinity capture or immunoprecipitation, the pellets were resuspended in 200 l of phosphate-buffered saline ified from H25B10 cells (ATCC No. CRL 8017). The plate was sealed and incubated at 4°C overnight. The antibody (PBS) solution.
solution was then replaced with 0.1% bovine serum albumin (BSA) and 0.02% sodium azide (NaN 3 ) in PBS and Isolation of intracellular HBV core particles Transfected HepG2 cells in 60-mm tissue culture dishes incubated further at 4°C for at least 2 h. were lysed by the addition of lysis buffer (10 mm TrisHCl (pH 7.5), 50 mm NaCl, 1 mm EDTA, 0.25% Nonidet Immunoaffinity capture of HBV particles: The coated plate was washed three times with 0.01% Tween 20 and 0.02% P-40, and 8% sucrose) and incubated for 2-5 min at room temperature. The cell lysate was collected and subjected NaN 3 in PBS (PBS/T/N) and filled with 10 l of 0.035% Tween 20 and 0.02% NaN 3 in PBS and 25 l of each extrato microcentrifugation to remove nuclei and cellular debris. To eliminate transfected plasmids and cytoplascellular viral solution purified from culture media of transfected HepG2 cells, as described above. The samples mic RNA, the lysate was incubated with 6 mm MgCl 2 , 100 g/ml of DNase I, and 10 g/ml of RNase A at 37°C
were further incubated at 4°C overnight and washed five times with PBS/T/N and twice with PBS. The solution for 30 min. The viral core particles were precipitated by the addition of one-third volume of 26% PEG 8000, 1.4 m was pipetted up and down for efficiently washing during each wash. NaCl, and 25 mm EDTA followed by centrifugation. The pellets were then suspended in appropriate solutions as described above.
Detection of the captured HBV particles: To isolate DNA of the complete HBV particles bound to the antibody, a denaturing solution (0.09 n NaOH and 0.01% NP-40) was Endogenous polymerase assay Viral materials pelleted from culture media or cell lysates added to each well. The sample was incubated at 37°C for 1 h and subsequently neutralized with an equal volwere suspended in 30 l polymerase buffer. To the mix-
